CytoReason
PrivateLast Round
Debt
Jul 17, 2024
Total Funding Raised
$157M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
CytoReason operates in Healthcare & Life Sciences and is based in Tel Aviv. Its latest recorded funding round was a Debt round in July 2024.
CytoReason is a health tech company that develops an AI-powered computational disease modeling platform to help pharmaceutical and biotechnology companies make data-driven R&D decisions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoReason Comparables
Compare CytoReason with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aitia | 82% | |
| Insilico Medicine | 82% | |
| Protai | 79% |
For institutional investors. Book with your work email.
CytoReason Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jul 17, 2024 | ||||
| Strategic | Sep 20, 2022 | ||||
| Series A | Jun 1, 2021 | ||||
| Seed | Jan 1, 2020 | ||||
| Seed | Nov 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CytoReason Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pontifax Venture Capital | Seed |
| Pico Venture Partners | Series A, Seed |
| M&G Investments | Debt |
| Pfizer | Debt, Strategic |
| Bank Hapoalim | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 93% MoM.
- Aug 21, 2026
Monthly visitors increased 613% MoM.
For institutional investors. Book with your work email.
CytoReason Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CytoReason's valuation, stock price, and market status.
Is CytoReason a public or private company?
CytoReason is a private company.
What is the current stock price of CytoReason?
CytoReason is a private company, so its shares have no public market price. Caplight tracks CytoReason's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CytoReason worth (valuation)?
Valuation information for CytoReason is not publicly available.
Can I buy CytoReason stock?
CytoReason shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CytoReason's last funding round?
CytoReason's most recent funding round was Debt on July 17, 2024.
Who are the main investors in CytoReason?
Key investors in CytoReason include M&G Investments, Pfizer.
Will CytoReason IPO soon?
No public IPO plans have been announced for CytoReason.
How can I track CytoReason secondary market activity?
Caplight tracks bids, offers, and trades in CytoReason's shares on secondary markets.